



**Oregon State
University**

Carlson College of Veterinary Medicine

cvmresearch@oregonstate.edu

RESEARCH RELATED TOPICS
JANUARY 2019 EDITION

Biomedical Sciences Seminar Series

Tuesday, January 15, 2019

Tuesday, January 15, 2019, 12:00-1:00pm, Magruder 102, Chad Clancy, D.V.M., Resident, Utah State University, Candidate OSU Assistant Professor Anatomic Pathology, "TBA".

Tuesday, January 17, 2019

Tuesday, January 17, 2019, 12:00-1:00pm, Magruder 102, Kelly Hughes, D.V.M., Candidate OSU Assistant Professor Anatomic Pathology, "TBA".

Monday, January 22, 2019

Tuesday, January 22, 2019, 12:00-1:00pm, Magruder 102, Mike Betley, D.V.M., Candidate, OSU Assistant Professor Anatomic Pathology, "TBA".

Tuesday, January 29, 2019

Tuesday, January 29, 2019, 12:00-1:00pm, Magruder 102, Amanda Tamer-Rait, University of Nebraska/Lincoln, Candidate, OSU Assistant Professor Anatomic Pathology, "Microbial Control of Metabolic Health".

Tuesday, February 5, 2019

Tuesday, February 5, 2019, 12:00-1:00pm, Magruder 102, Florian Hansmann, Ph.D., Candidate, OSU Assistant Professor Anatomic Pathology, "TBA".

Tuesday, February 19, 2019

Tuesday, February 19, 2019, 12:00-1:00pm, Magruder 102, Mary Weber, Ph.D., University of Iowa, "TBA".

Tuesday, February 26, 2019

Tuesday, February 26, 2019, 12:00-1:00pm, Magruder 102, Kevin Haussler, D.V.M., D.C., Ph.D., "TBA".

Biochemistry and Biophysics Seminar Series

Wednesday, January 30, 2019

Wednesday, January 30, 2019 at 3pm in ALS 4001, Dr. Jodi Nunnari, University of California, Davis, "Mitochondrial Behavior".

Microbiology Seminar Series

Thursday, January 24, 2019

Wednesday, January 24, 2019 at 3pm in LPSC 402, Michael Freitag, Professor, Biochemistry & Biophysics, Oregon State University, Corvallis, “Chromatin-mediated gene silencing and genome stability in filamentous fungi”.

College of Public Health & Human Sciences Seminar Series

All seminars are 1:00 – 2:00 pm, Tammy Bray Leadership Conference Room (Hallie Ford Center #115).

Friday, January 25, 2019.

Alison Naleway, Ph.D. Senior Investigator, Associate Director of Science Programs, Kaiser Permanente Center for Research, Portland, OR, “Evaluating Human Papillomavirus Vaccine Safety and

Upcoming Funding Deadlines

Deadline January 11, 2019

PAR-16-254 Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01)

Application Due Date(s) by 5:00 PM local time of applicant organization, January 11, 2019, by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s), by 5:00 PM local time of applicant organization; January 11, 2019, by 5:00 PM local time** of applicant organization. All types of [applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type New. Related Notices [May 27, 2016](#) - Notice of Change to Key Dates in PAR-16-254. See Notice [NOT-AI-16-054](#).

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-254.html>

This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

Deadline January 18, 2019

Alzheimer's Drug Discovery Foundation Drug Discovery Program

<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-discovery>

The Alzheimer's Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer's disease, related dementias, and cognitive aging by supporting promising therapeutic approaches. The ADDF's Drug Discovery RFP focuses on supporting programs that aim to:

- 1) Advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or
- 2) Build preclinical evidence in relevant animal models for repurposed/repositioned drugs.

Average awards range from \$150,000 to \$600,000 based on stage and scope of research.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline January 18, 2019

Alzheimer's Drug Discovery Foundation Neuroimaging and CSF Biomarker Development

<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers>

This RFP supports the development and validation of neuroimaging and CSF biomarkers to enhance clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

\$150,000-\$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline January 18, 2019

Alzheimer's Drug Discovery Foundation Prevention Beyond the Pipeline

<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline>

The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. The average award for epidemiological analysis is \$50,000 - \$100,000. Other research awards up to \$3 million based on stage and scope of research

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline January 25, 2019

American Institute for Cancer Research Investigator-Initiated Grant Program

http://www.aicr.org/research/grant/research_funded_grant_programs.html

Our Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes.

Individual grants offer a maximum funding of \$150,000 plus 10 percent indirect costs provided over a two-year term. A limited number of three-year term Investigator-Initiated Research Grants (maximum of \$225,000 plus 10 percent indirect costs) may be funded. The three-year grants are only awarded to support the conduct of epidemiologic or intervention studies that cannot feasibly be conducted within the 2 year period.

Principal Investigators must have a PhD, MD, or equivalent degree, and be research staff or a faculty member at a non-profit academic or research institution at the level of Assistant Professor (or its equivalent) or higher.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline January 25, 2019

Pfizer, Inc. 2019 Rheumatology Competitive Grant Program

<https://www.pfizer.com/science/collaboration/medical-research-grants>

The intent of this Request for Proposal (RFP) is to support both clinical and basic science research on the pathogenesis and treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylarthritis (AS), and/or Systemic Lupus Erythema (SLE) with a specific focus on projects that are most relevant to improving patient care.

All US investigators are encouraged to apply, including Young investigators who are in the early stages of their career. \$150,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline January 25, 2019

PAR-17-003 Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 25, 2019).

Application Due Date(s) February 27, 2019; July 11, 2019; October 28, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<http://grants.nih.gov/grants/guide/pa-files/PAR-17-003.html>

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians,

statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Deadline January 25, 2019

PAR-16-322 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R24)

Application Due Date(s) Standard dates January 25, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) apply by 5:00 PM local time** of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type Reissue of [PAR-13-252](#). Related Notices None.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-322.html>

This FOA encourages applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

This FOA encourages applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The Division of Comparative Medicine (DCM) in ORIP and representatives from other NIH Institutes convened an NIH workshop in 2012 that addressed the current status of animal stem cell biology and made recommendations concerning improvements in technologies and applications of animal stem cells to regenerative medicine see

https://dpcpsi.nih.gov/sites/default/files/orip/document/summary_of_the_improving_animal_models.pdf.

The results of this workshop provide the basis for this FOA. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Background Information Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to damage or congenital defects. Regenerative medicine has the potential to solve the problem of the shortage of organs available for donation. It also holds the promise of repairing or replacing damaged tissues and organs in the body by stimulating organs previously considered irreparable to heal themselves. The recent discovery of the reprogramming of adult cells to a pluripotent state provides opportunities to address a major problem of regenerative medicine, immune rejection of transplanted tissue. The ability to generate differentiated cells and tissues using cells from specific patients will facilitate individualized medicine and eventually will lead to specialized therapies. The field is moving toward translation to clinical practice and is becoming increasingly dependent on animal models and information regarding the potential therapeutic efficacy of new technologies. Generating the correct type and quantity of the specific cell types required for replacement therapy is a significant challenge, as are the problems associated with introducing these cells into the proper environment in vivo and overcoming immune reactions. Finding solutions to these problems will require extensive testing in experimental animal models.

Major advances have been made in the past several years in deriving pluripotent cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) from both humans and animals. In parallel, other investigations have isolated and characterized multipotent “somatic” or “adult” stem cells from various tissues, including Mesenchymal Stem Cells (MSCs) and Germinal Stem Cells (GSCs). The discovery of mouse ESCs in 1981 revolutionized the field of developmental biology and provided new capability for genome manipulation and investigations of gene function. Isolation of human ESCs created new possibilities for the field of regenerative medicine. ES-like cells have been derived from a number of animal species, including rats, fish, cows, pigs and non-human primates. Many characteristics of animal ES-like cells, including surface markers, growth factor requirements, ability to differentiate and others can be quite different from human ESCs. There is

a continuing expansion in the number and type of stem cells which potentially can be used for stem cell therapy.

The field of stem cell research experienced a dramatic new direction with the isolation of iPSCs, derived by reprogramming somatic cells to a pluripotent state. Several studies on various animal systems suggest that the basic pluripotency network appears to be conserved among different species, allowing derivation of iPSCs from a variety of animals. Significant efforts are needed to improve reprogramming methods to generate safer iPSCs with higher efficiency and better quality.

MSCs, a type of somatic stem cell, were originally identified as a subpopulation of bone marrow cells with osteogenic potential. The properties of MSCs have been examined extensively over the past decade. Studies using animal models have shown promising results following MSC therapy for induced injury in the musculoskeletal, cardiovascular, digestive and nervous systems. In addition, many clinical trials have been initiated to test the efficacy of MSC infusion for treating various human diseases. Given the wide range of tissue sources, the recognition of subpopulations with specific properties, and the frequent production of genomic alterations upon expansion in cell culture, extensive characterization of MSCs and development of improved techniques are required. Most importantly, there is relatively limited understanding of the normal biological functions of MSCs and the mechanisms by which they participate in tissue repair.

GSCs are another type of somatic stem cell of great interest for regenerative medicine. They are an essential component of reproductive biology. Genetic manipulation of GSCs provides a powerful tool for producing transgenic animals, for elucidating mechanisms underlying germ cell development and differentiation and for understanding the interactions between stem cells and their niche. Further development of the methods for unlimited production of GSCs (for producing either sperm or eggs) will impact the ability to investigate the molecular basis of germ cell differentiation, explore the potential for germline stem cell therapy and treat infertility by transplantation. Numerous reports using animal and human GSCs have shown generation of pluripotent cells during in vitro cultivation, which potentially can solve a number of issues. However, it remains difficult to isolate, derive and maintain stable cultures of these cells from humans and model animal species. Furthermore, the mechanisms that determine the reprogramming of GSCs into pluripotent stem cells are not well understood and efficient methods for directed reprogramming of these still have to be developed.

Along with rodents, several other animal species are being developed as models for various studies in the field of regenerative medicine. Understanding the properties and capabilities of stem cells derived from animals such as fish, rabbits, dogs, pigs, sheep, goats and monkeys will increase the potential for the use of the most appropriate systems for modeling particular human disease conditions or for other medical applications. Non-rodent species, especially "large animal models" provide important advantages for transplantation studies, including large size, similarity to human physiology and pathology and longer life span, thus facilitating translation to studies in humans. The use of animal stem cells as a model for human cells in procedures related to regenerative medicine requires in-depth understanding of common regulatory pathways as well as species-specific properties and their impact on potential therapeutic applications.

Animal experiments have historically made a significant contribution to understanding human disease. However, animal studies need to be improved in order to increase reproducibility of the studies and better predict the effectiveness of treatment strategies in clinical trials. Several possible causes of the disparity between the results of animal studies and clinical trials have been identified, including failure to acknowledge the limitations of animal models, inadequate animal data, less than optimal disease models and overestimation of treatment efficacy due to the preferred publishing of positive results. These problems should be addressed in the design and execution of preclinical, animal-based studies involving stem cell based therapies.

Deadline January 26, 2019

RFA-HL-19-024 Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 26, 2019).

Application Due Date(s) February 26, 2019, September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021), by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) May 8, 2019, September 10, 2019, May 8, 2020, September 10, 2020, May 6, 2021, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-024.html>

Announcement Type Reissue of [RFA-HL-16-008](#).

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences.

Deadline January 31, 2019

PA-17-055 NIH Summer Research Experiences for Students and Science Teachers (Admin Supp)

Current Closing Date for Applications: January 31, 2019.

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=290142>

The National Institutes of Environmental Health Sciences hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) with R01, R21, R15, R35, R37, or P01 awards that funds are available for administrative supplements to support summer research experiences in environmental health science for high school students, college undergraduates, masters degree candidates, medical students, secondary school science teachers, and science professors from R15/AREA grant eligible institutions. Administrative supplements must support work within the scope of the original project. Award amount not specified.

Deadline January 31, 2019

Oregon Department of Agriculture Specialty Crop Block Grant Program (SCBGP)

https://www.oregon.gov/ODA/programs/MarketAccess/SpecialtyCrop/Pages/SpecialtyCrop.aspx?utm_medium=email&utm_source=govdelivery

ODA is requesting 15-page grant proposals from applicants describing their proposed projects. Proposals should be submitted online and must be received by Thursday, January 31, 2019 at 12:00 noon Pacific Standard Time. Funding requests: \$25,000 to \$175,000, and projects must be completed within 2.5 years. Match is strongly encouraged. ODA encourages interested parties to work regionally to submit collaborative project proposals that benefit Oregon growers and processors as well as partners in other states that share common specialty crops. Those who have received specialty crop grant funds in the past are also encouraged to apply, whether they are interested in building on an existing project or if they are proposing a new project. Crops that are eligible: Fruits, Vegetables, Tree nuts, Dried fruits, Christmas trees, Turf type grasses, Nursery crops (including floriculture and horticulture). \$175,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 1, 2019

FY19 JWMP Advancement of Previous Department of Defense (DoD) or Service Funded Medical Research and Development (R&D) Projects, Solicitation Number: W81XWH-19-RFI-JWMP

Agency: Department of the Army

Office: U.S. Army Medical Research Acquisition Activity

<https://www.fbo.gov/index.php?s=opportunity&mode=form&id=20e4f6077dc1e72dd868d098f40d7b46&tab=documents&tabmode=list>

1.0 SUBJECT: **The Joint Warfighter Medical Research Program (JWMP)**, managed by the Congressionally Directed Medical Research Programs (CDMRP) at the US Army Medical Research and Materiel Command, provides an opportunity to advance previously funded DoD or Service medical R&D projects that address the medical requirements of the Services. The JWMP complements and enhances the

Defense Health Program by facilitating the further development of promising industry and academic efforts. Each year a broad spectrum of R&D initiatives are considered under the JWMP. The science and technology development efforts are aligned to one of the six Joint Program Committee (JPC) scientific domains. These are: Medical Simulation and Information Sciences (JPC-1), Military Infectious Diseases (JPC-2), Military Operational Medicine (JPC-5), Combat Casualty Care (JPC-6), Radiation Health Effects (JPC-7), and Clinical and Rehabilitative Medicine (JPC-8). Through research efforts focused in advanced technology development and product demonstration and validation, the JWMP offers a pathway to transition maturing medical solutions to the Military Health System (MHS) for the benefit of our Service members and other MHS beneficiaries. In accordance with the Congressional language, the funds appropriated for the JWMP shall be used to augment and accelerate high priority DoD and Service medical requirements and to continue prior year initiatives that are close to achieving their objectives and yield a benefit to military medicine. These funds shall not be used for new projects or for basic research.

2.0 DISCLAIMER: This Request for Information (RFI) is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained.

Deadline February 1, 2019

Spencer Organization - Small Research Grants Program

<https://www.pep-net.org/spencer-foundation-small-research-grants-program>

Deadlines: Small Research Grant proposals are accepted 4 times per year. The next deadline is at 4:00pm CDT, May 1, 2018. The following deadlines will fall on **November 1, 2018, and February 1, 2019.**

<https://www.spencer.org/small-research-grants>

The Small Research Grants program aims to support smaller scale or pilot research projects that have budgets of \$50,000 or less. Proposals are encouraged from scholars across a variety of disciplines in an effort to fund field-initiated education research.

In September 2017, ahead of the November deadline, we hosted an informational webinar in which we gave an overview of the program and proposal submission process. You can access the slides from the webinar and a recording of the webinar itself below, but please note that the dates mentioned are no longer applicable and the online application has been slightly updated.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 5, 2019

PAR-17-267 Modeling of Infectious Disease Agent Study Research Projects (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization.

AIDS Application Due Date(s) Standard AIDS dates apply by 5:00 PM local time of applicant organization.

All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-267.html>

The threat of emergence or re-emergence of infectious disease epidemics continues to be a concern of policymakers and the public health services. Better tools and methods are needed to improve our knowledge of the dynamics of emergence, surveillance and detection of events, and the effectiveness and implications of prevention and mitigation efforts. The variety of possible scenarios complicates the challenge of confronting these threats. An important role of science is to create a rational picture of the alternatives by collecting, analyzing, and interpreting relevant data and by developing models. The models themselves can guide the collection of further data. In addition, good models can reveal important patterns in the data which allow investigators to examine scenarios and to understand likely consequences of interventions. These capabilities can help responsible parties plan for and respond to an emerging epidemic or a bioterrorist threat.

The Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models can be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. MIDAS has produced a number of software packages to help local, state and federal public health officials prepare for and respond to infectious disease emergencies. MIDAS trains public health officials in using modeling tools to understand how to prepare for and respond to infectious disease threats.

Information on current and previous MIDAS activities, publications, and reports can be found on the MIDAS website at <https://www.nigms.nih.gov/Research/specificareas/MIDAS/Pages/default.aspx>.

Deadline February 5, 2019

PA-18-725 Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date(s) Not Applicable.

Application Due Date(s) February 5, 2019, June 5, 2019, October 5, 2019 by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. AIDS Application Due Date(s) Not Applicable.

https://grants.nih.gov/grants/guide/pa-files/PA-18-725.html?utm_campaign=+31822883&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=

Announcement Type New. **Related Notices** None.

Companion Funding Opportunity [PA-18-724, R21](#) Exploratory/Developmental Grant

The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Deadline February 5, 2019

PAR-16-093 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)

Application Due Date February 5, 2019, Standard dates apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) New Date per issuance of [NOT-OD-16-069](#): **Standard AIDS dates apply by 5:00 PM local time** of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-093.html>

This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Deadline February 5, 2019

PAR-16-228 Metabolic Reprogramming to Improve Immunotherapy (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA AIDS Application Due Date(s) [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-093.html>

The overall goal of this funding opportunity announcement (FOA) is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses *in vivo*, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Deadline February 5, 2019

PAR-17-244 Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)

Announcement Type Reissue of [PAR-16-058](#).

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-244.html>

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. AIDS Application Due Date(s) Not Applicable.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for collaborative R01 projects from multi-disciplinary teams to expand, improve, or transform the reliability and utility of mammalian cancer and tumor models for translational research. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address translational modeling research questions beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions.

With this FOA, the NCI intends to encourage submission of multidisciplinary projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, teams of applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Deadline February 5, 2019

PAR-17-245 Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. AIDS Application Due Date(s) Not Applicable.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-245.html>

Announcement Type Reissue of [PAR-16-059](#). Companion Funding Opportunity [PAR-17-244](#), Collaborative [R01](#) Grant.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Deadline February 5, 2019

Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)

Open Date (Earliest Submission Date) January 5, 2019.

Letter of Intent Due Date(s) Not Applicable.

Application Due Date(s) [Standard dates](#) (**February 5, June 5, October 5, 2019**) apply, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA is February 5, 2019

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) [Standard AIDS dates](#) apply, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates. **The first AIDS application due date for this FOA is May 7, 2019.**

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Companion Funding Opportunity [PA-19-073](#), [R21](#) Exploratory/Developmental Grant

<https://grants.nih.gov/grants/guide/pa-files/PA-19-074.html>

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

Deadline February 5, 2019

PA-17-283 Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Standard AIDS dates apply by 5:00 PM local time of applicant organization.

All [types of applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type New. Related Notices None.

Companion Funding Opportunity [PA-17-282](#) [R21](#) Exploratory/Developmental Grant.

<https://grants.nih.gov/grants/guide/pa-files/PA-17-283.html>

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.

Deadline February 6, 2019

Burroughs Wellcome Fund

<https://www.bwfund.org/grant-programs/regulatory-science/innovation-regulatory-science>

BWF's Innovation in Regulatory Science Awards provides up to \$500,000 over five years to academic investigators developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions the Food and Drug Administration (FDA) and others make. This would necessarily draw upon the talents of individuals trained in mathematics, computer science, applied physics, medicine, engineering, toxicology, epidemiology, biostatistics, and systems pharmacology, to name a few. All applicants will be required to complete a web-based questionnaire assessing their eligibility to apply for this award. If eligibility criteria are met, applicants will be automatically directed to the web-based proposal form. \$500,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 6, 2019

RFA-AG-19-029 Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (R01 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-19-029.html>

Letter of Intent Due Date(s) February 6, 2019.

Application Due Date(s) March 6, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this Funding Opportunity Announcement.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission. The importance of circadian rhythm in tissue homeostasis, sleep regulation and behavior is well recognized. However, systematic studies on how dietary composition, feeding regimens and circadian regulation may converge to improve healthspan are lacking. Dietary interventions (DI) have been demonstrated to improve both healthspan and longevity, with caloric restriction (CR) as one of the most effective strategies in animal species ranging from lower organisms to nonhuman primates. While energy sensing pathways (mTOR, Sirtuins and AMPK) are important for the DI effects, the molecular mechanisms that could be leveraged for translation remain elusive. Recently, circadian regulation has been recognized as a novel mediator for DI effects in mice, through several studies that have indicated interactions between the circadian clock and major longevity pathways including sirtuins, insulin/IGF and mTOR signaling cascades. Interestingly, mice deficient in BMAL1, the core component of the peripheral circadian clock, fail to respond to DI-mediated lifespan extension and associated changes in plasma IGF-1 and insulin levels. In addition, entraining the peripheral circadian clocks by time-restricted feeding results in improved healthspan, even in the absence of DI. These findings thus provide an exciting opportunity to investigate circadian regulation of DI and associated physiological consequences.

Despite current data supporting the importance of circadian regulation of DI, molecular components that couple circadian systems with metabolic control, epigenetic modification and age-associated pathologies are not fully understood. In addition, little is known about the contributions of central clocks versus peripheral clocks for regulating circadian homeostasis in the context of aging and metabolism. Several DI modifications such as amino acid restriction, intermittent fasting, and fasting-mimicking diets have been shown to improve healthspan in animals and in human trials. Therefore, this FOA aims to examine how each of these dietary interventions entrains peripheral clocks and how circadian regulation integrates with various dietary strategies to achieve optimal health benefits.

To achieve an in-depth understanding of the basic biology of interplay between alterations of circadian rhythms and fasting/feeding cycles in promoting healthspan, this FOA encourages comprehensive, collaborative research projects that would increase our knowledge of mechanistic links between peripheral or central circadian regulation of promising dietary interventions in the following areas:

1. Age-related changes in circadian amplitudes, expression of clock-controlled genes and associated physiological consequences;
2. Changes with age in the molecular crosstalk between central and peripheral clocks;
3. The impact and molecular mechanisms of different dietary interventions aimed at altering aging on circadian gene and protein expression as well as epigenetic modification and metabolomic changes;

4. Changes with age in the tissue-specific mechanisms in peripheral or central circadian regulation in response to systematically varied dietary interventions;
5. Physiological consequences of circadian gene mutations that alter the efficacy for healthspan manipulations;
6. Identification of novel circadian genes that modulate DI responses;
7. Identification of novel diet-susceptible genes that might impact circadian clock entrainment; and
8. Systems biology approaches to discover novel networks connecting circadian regulation and dietary interventions to impact healthspan during aging

Deadline February 7, 2019

PAR-17-172 Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-172.html>

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) New Applications: February 7, 2019; and October 7, 2019.

Resubmission and Revision Applications: June 21, 2018, February 21, 2019, and October 21, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) July 3, 2018; March 15, 2019; and November 4, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

Components of Participating Organizations National Center for Complementary and Integrative Health (NCCIH).

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-17-174. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<http://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Deadline February 7, 2019

PAR-17-174 Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 6, 2019).

Application Due Date(s) New Applications: February 7, 2019 and October 7, 2019.

Resubmission and Revision Applications: February 21, 2019, and October 21, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) July 3, 2018; March 15, 2019; and November 4, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-174.html>

Companion Funding Opportunity PAR-17-172 U24 Resource-Related Research Projects – Cooperative Agreements. PAR-16-418, R61/R33 Exploratory/Developmental Phased Award. PAR-16-419, R33 Exploratory/Developmental Grants Phase II. PAR-17-216, U01 Research Project – Cooperative Agreements U01. Number of Applications See Section III. 3. Additional Information on Eligibility.

This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated multi-site clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating

Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism.

In addition, an accompanying Data Coordinating Center application, submitted under [PAR-17-172](#), proposing a data analysis and data management plan for the clinical project is required. **Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.**

Deadline February 8, 2019

RFA-AI-18-054 U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-054.html>

Open Date (Earliest Submission Date) February 8, 2019.

Letter of Intent Due Date(s) February 8, 2019.

Application Due Date(s) March 8, 2019, by 5:00 PM local time of applicant organization. All **types of non-AIDS applications** allowed for this funding opportunity announcement are due on this date.

AIDS Application Due Date(s) March 8, 2019, by 5:00 PM local time of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on this date.

The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States (U.S.) and Brazil under the U.S.-Brazil Collaborative Biomedical Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; neurological disorders and stroke, and environmental health sciences. This program represents an outstanding opportunity for U.S. and Brazil scientists to pursue collaborative research partnerships that address public health topics of mutual benefit to both nations.

Deadline February 8, 2019

19-542 National Science Foundation Mid-scale Research Infrastructure Program

Letter of Intent February 8, 2019

Deadline for application March 11, 2019

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=311063>

The Mid-scale Research Infrastructure Program is aimed at transforming scientific and engineering research fields as well as science, technology, engineering and mathematics (STEM) education research fields by making available new capabilities, while simultaneously training early-career researchers in the development, design, and construction of cutting-edge infrastructure. The NSF Mid-scale Research Infrastructure-2 Program (Mid-scale RI-2) supports implementation of projects that comprise any combination of equipment, instrumentation, computational hardware and software, and the necessary commissioning and human capital in support of implementation of the same. The Mid-scale RI-2 Program emphasizes strong scientific merit and response to an identified need of the research community, technical and managerial readiness for implementation, and a well-developed plan for student training and involvement of a diverse workforce in mid-scale facility development, and/or associated data management. Inclusion of voluntary committed cost sharing is prohibited. Application process: LOI required (2/8/2019), preliminary proposal (3/11/2019), invited full proposal (8/2/2019). Individual awards from \$20 million to \$70 million are anticipated for advanced design and implementation, pending availability of funds. Duration of the award may be up to five (5) years

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 8, 2019

Pfizer, Inc. 2019 Inflammatory Bowel Disease Competitive Grant Program

<https://www.instrumentl.com/grants/aspire-rheumatology-dermatology-and-inflammatory-bowel-disease-research-grant>

The intent of this Request for Proposal (RFP) is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge of the epidemiology, pathogenesis and treatment of Inflammatory Bowel Disease (IBD).

The overall focus of the competitive research grants program is to support both clinical and basic science research on the pathogenesis and treatment of IBD with a specific focus on projects that are most relevant to improving patient care.

All US investigators are encouraged to apply, including young investigators who are in the early stages of their career. **Grant amount:** Up to US \$150,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 8, 2019

PAR-19-100 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Open Date (Earliest Submission Date) February 8, 2019.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) March 8, 2019, July 11, 2019, November 9, 2019, March 8, 2020, July 11, 2020, November 9, 2020, March 8, 2021, July 11, 2021, November 9, 2021, by 5:00 PM local time of applicant

organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement Type Reissue of [PAR-18-245](#).

<https://grants.nih.gov/grants/guide/pa-files/PA-19-100.html>

The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from two or more CTSA Program hub institutions (see below under Eligible Individuals) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.

Deadline February 12, 2019

PA-19-124 Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PA-19-124.html>

Reissue of [PA-18-396](#)

Application Due Date(s) [Standard dates \(February 12, June 12, October 12, 2019\)](#) apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not

been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ([PA-19-125](#)).

Deadline February 12, 2019

PA-19-132 Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)

Application Due Date(s) [Standard dates \(February 12, June 12, October 12, 2019\)](#) apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PA-19-132.html>

Reissue of [PA-18-371](#). Companion Funding Opportunity [PA-19-131](#).

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ([PA-19-131](#)).

Deadline February 15, 2019

Daiichi-Sankyo TaNeDs Global 2019

https://www.daiichisankyo.com/rd/ta_neds/index.html

TaNeDS program provides close partnership between you and scientists in Daiichi Sankyo to tackle unmet medical needs. The program is open to principal investigators affiliated with research institution in academia and small biotech located in Europe and the United States. Research interests include: oncology, pain/neuroscience, cardiovascular and renal diseases, rare diseases, other diseases, cell therapy, technology and related research. Type A awards range from \$50,000 to \$75,000 per year, plus overhead. Type B awards range from \$100,000 to \$150,000 per year, plus overhead. \$75,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 15, 2019

Medical Research Foundation (MRF) New Investigator Grant

<https://www.ohsu.edu/xd/about/foundation/about/medical-research-foundation/grants.cfm>

Maximum grant award: \$40,000. Two to three grants awarded quarterly.

Application deadline dates: February, May 15, August 15, November 15.

Through this award, the MRF supports promising new investigators in biomedical research. Principal investigators must be at the beginning of an independent career with a faculty position at one of Oregon's colleges or universities. A letter of support from the department chair or the institute director must accompany each application describing the independence of the principal investigator and the commitment of the unit to that investigator and their research program.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 15, 2019

Medical Research Foundation (MRF) Emergency Interim Support Grant

<https://www.ohsu.edu/xd/about/foundation/about/medical-research-foundation/grants.cfm>

Through this award, the MRF supports established investigators who are in need of bridge funding. The grant provides funding for research programs that have lost national grant funding, enabling investigators to develop data supporting application renewals. The application must contain a clear explanation of current grant funding and the status of grants in revision.

Maximum grant award: \$40,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 16, 2019

PAR-19-149 Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date) January 16, 2019

Letter of Intent Due Date(s) Not applicable

Application Due Date(s) [Standard dates \(February 16, June 16, October 16, 2019\)](#) apply, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) [Standard AIDS dates \(May 7, September 7, 2019\)](#) apply, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Reissue of [PA-18-286](#)

[PAR-19-150](#), [R21](#) Exploratory/Developmental Grant

<https://grants.nih.gov/grants/guide/pa-files/PAR-19-149.html>

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Deadline February 16, 2019

PAR-16-094 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)

Application Due Date February 16, 2019 apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. AIDS Application Due Date(s): **New Date** per issuance of [NOT-OD-16-070](#): **Standard AIDS dates apply by 5:00 PM local time of applicant organization**. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. <https://grants.nih.gov/grants/guide/pa-files/PAR-16-094.html>. Reissue of [PAR-13-115](#).

This FOA encourages Exploratory/Developmental Research grant (R21) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Deadline February 16, 2019

PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)

Application Due Date February 16, 2019 apply by 5:00 PM local time of applicant organization. All **types of non-AIDS applications** allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) Standard AIDS dates** apply. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PA-16-175.html>

This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. This FOA will utilize the exploratory/developmental research grant (R21) mechanism to foster cancer etiology and epidemiology research. While these studies may involve considerable risk, they may also lead to a breakthrough in a particular area, and to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, or clinical).

Deadline February 16, 2019

PA-17-282 Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)

Application Due Date February 16, 2019, apply by 5:00 PM local time of applicant organization. All **types of applications** allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Standard AIDS dates, apply by 5:00 PM local time of applicant organization. All **types of applications** allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PA-17-282.html>

The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. The goal will be to support research to identify and elucidate the pathogenic mechanisms underlying the interactions among TB, T2DM (as well as pre-diabetes), and HIV, their role in immune dysregulation, and their impact on disease development, progression, and treatment outcomes. Understanding the basis of this dysregulation will allow identification and development of targeted therapies to improve treatment options among those with TB and T2DM with and without HIV. People living with HIV are well recognized to be at increased risk for developing TB, in large part due to the loss of CD4 T cells. However, even under anti-retroviral therapy treatment HIV+ individuals are still at an increased risk of developing active TB, as are individuals with T2DM. Chronic HIV infection is also associated with metabolic abnormalities such as insulin resistance, impaired glucose tolerance, and metabolic syndrome. The immunopathogenic effects of T2DM also result in significantly increased risk of TB activation and make TB therapy less effective, resulting in higher failure, relapse, and death rates. Additionally, pre-diabetes, where blood glucose levels are elevated but not to

levels defined as T2DM, has also been reported to suppress immunity to TB, significantly increasing the risk of developing active TB. The mechanisms behind the increased risk of TB for T2DM and HIV co-infection, and their potential overlap, are yet to be fully elucidated. A chronic “metainflammatory” state, and immuno-metabolic dysregulation have been implicated. T2DM and HIV subvert essential immune cell functions for TB by dysregulating cell regulatory signaling pathway, often altering cellular metabolic activity.

Deadline February 21, 2019

RFA-CA-19-009 U.S.-China Program for Biomedical Collaborative Research (R01 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-009.html>

Announcement Type Reissue of [RFA-AI-16-006](#)

Open Date (Earliest Submission Date) January 21, 2019.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) February 21, 2019, by 5:00 PM local time of applicant organization. All **types of non-AIDS applications** allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this Funding Opportunity Announcement.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) February 21, 2019, by 5:00 PM local time of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this Funding Opportunity Announcement.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively. U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.

Deadline March 6, 2019

19-541 National Science Foundation Future of Work at the Human-Technology Frontier: Core Research

https://www.grants.gov/web/grants/view_opportunity.html?oppld=310898

The specific objectives of the Future of Work at the Human-Technology Frontier program are (1) to facilitate convergent research that employs the joint perspectives, methods, and knowledge of computer science, engineering, learning sciences, research on education and workforce training, and social, behavioral, and economic sciences; proposals must clearly define the work and work context addressed by the research. Technology should be integrated with learning sciences, research on education and workforce training, and social, behavioral, and economic science perspectives to advance the science of the human-technology team. Potential results should contribute to fundamental advances in the science and technology of future workforce development and education, work environments, and positive work outcomes for workers and society at large. FW-HTF Planning Grants (FW-HTF-P, \$150,000): FW-HTF-P are intended to stimulate research capacity through multidisciplinary team-building and the development of high-impact, fundamental research concepts. FW-HTF Research Grants (FW-HTF-R): FW-HTF-R must advance fundamental understanding of the human-technology partnership in the context of future work, describing potential improvements to work, workplaces, workforce preparation, and work outcomes for workers and society. Medium FW-HTF-R awards will provide support for a period of up to 3 years, with a total budget request not exceeding \$1,500,000. Large FW-HTF-R awards will provide support for a period of up to 4 years, with a total budget request between \$1,500,001 and \$3,000,000.

Deadline March 12, 2019

Cystic Fibrosis Foundation Awards for Gene Editing for Cystic Fibrosis

<https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/Awards-for-Gen-Editing-for-Cystic-Fibrosis/>

The Cystic Fibrosis Foundation announces a Request for Applications (RFA) to identify and support highly meritorious proposals in gene editing that offer potential to repair or circumvent CFTR mutations in individuals with CF. To bring new technologies to the CF field, investigators without experience in CF research are encouraged to apply.

Collaborative Award - Up to \$250,000 over three years.

Pilot and Feasibility Award - Up to \$150,000 over two years.

Postdoctoral Fellowship Award - First-year up to \$63,100/second-year up to \$65,450.

Research Award - Up to \$600,000 over three years.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline April 30, 2019

PAR-17-173 Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)

Letter of Intent Due Date(s) 30 days prior to the application due date (April 30, 2019).

Application Due Date(s) New Applications: May 31, 2019; and January 31, 2020.

Resubmission and Revision Applications: June 14, 2019; and February 14, 2020 by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) March 2, 2018; October 31, 2018; June 28, 2019; and February 28, 2020; by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Components of Participating Organizations National Center for Complementary and Integrative Health (NCCIH).

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-173.html>

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under [PAR-17-175](#). The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<http://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Deadline May 20, 2019

RFA-MH-18-200 NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01)

Letter of Intent Due Date(s) 30 days prior to the application due date May 20, 2018.

Application Due Date(s) June 20, 2018, June 20, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) Not Applicable. Announcement Type Reissue of [RFA-MH-15-600](#).

<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-200.html>

The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the [NIMH Strategic Plan](#) and the [Research Domain Criteria \(RDoC\)](#) project.

Deadline May 20, 2019

RFA-MH-19-130 NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

Open Date (Earliest Submission Date) May 20, 2018.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) June 20, 2018 and June 20, 2019, by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Not Applicable.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-130.html>

Announcement Type Reissue of [RFA-MH-18-200](#).

The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the [NIMH Strategic Plan](#) and the [Research Domain Criteria \(RDoC\)](#) project.

Deadline June 4, 2019

RFA-HL-19-015 Physician-Scientist (PS) Research Award for Early Stage Investigators (ESIs) (R01 - Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-015.html>

Open Date (Earliest Submission Date) May 4, 2018.

Letter of Intent Due Date(s) 30 days before the application due date.

Application Due Date(s) June 4, 2018, June 4, 2019, June 4, 2020, by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 10, 2018, September 10, 2019, September 10, 2020, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

The Physician-Scientist Research Award for Early Stage Investigators is intended to support the independence of physician-scientist faculty committed to academic careers in heart, lung, and blood diseases and sleep disorders (HLBS) research, and related implementation science.

Deadline June 25, 2019 LOI

RFA-DA-18-020 NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

Letter of Intent Due Date(s) June 25, 2019, 30 days prior to the application due date.

Application Due Date(s) July 25, 2019, July 25, 2020, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 7, 2019, September 7, 2020 by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Activity Code [UG3/UH3](#) Exploratory/Developmental Phased Award Cooperative Agreement

Announcement Type Reissue of [RFA-DA-18-003](#).

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-020.html>

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

Deadline June 27, 2019

RFA-HG-18-002 Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date) June 27, 2019.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) June 27, 2019; June 26, 2020, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 10, 2018; September 10, 2019; September 10, 2020 by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-18-002.html>

This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than an order of magnitude) improvement in DNA sequencing, and practical methods for direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Deadline July 14, 2019

RFA-DA-18-019 NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)

Activity Code [DP1](#) NIH Director's Pioneer Award (NDPA). Announcement Type Reissue of [RFA-DA-18-001](#).

Letter of Intent Due Date(s) 30 days prior to the application due date (July 14, 2018).

Application Due Date(s) August 14, 2019; August 14, 2020), **by 5:00 PM local time** of applicant organization. All **types of applications** allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) August 14, 2019;** August 14, 2020 **by 5:00 PM local time** of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on these dates.

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>.

The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

Deadline July 16, 2019

PD-16-004Y Science of Learning

https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5567

Deadline(s) for applications: January 16, 2019, and July 10, 2019.

The Science of Learning program supports potentially transformative basic research to advance the science of learning. The goals of the SL Program are to develop basic theoretical insights and fundamental knowledge about learning principles, processes and constraints. Projects that are integrative and/or interdisciplinary may be especially valuable in moving basic understanding of learning forward but research with a single discipline or methodology is also appropriate if it addresses basic scientific questions in learning. The possibility of developing connections between proposed research and specific scientific, technological, educational, and workforce challenges will be considered as valuable broader impacts, but are not necessarily central to the intellectual merit of proposed research. The program will support research addressing learning in a wide range of domains at one or more levels of analysis including: molecular/cellular mechanisms; brain systems; cognitive affective, and behavioral processes; and social/cultural influences. The program supports a variety of methods including: experiments, field studies, surveys, secondary-data analyses, and modeling. Examples of general research questions within scope of the Science of Learning program include; How does learning transfer from one context to another or from one domain to another? How is learning generalized from specific experiences? What is the basis for robust learning that is resilient against potential interference from new experiences? How is learning consolidated and reconsolidated from transient experience to stable memory? How does the structure of the learning environment impact rate and efficacy of learning? For example, how do timing, content, learning context, developmental time point and type of engagement (e.g., active learning, group learning) impact learning processes and outcomes?; How can we integrate research findings and insights across levels of analysis, relating understanding of cellular and molecular mechanisms of learning in the neurons to circuit and systems-level computations of learning in the brain, to cognitive, affective, social, and behavioral processes of learning? What concepts, tools, or questions will provide the most productive linkages of across levels of analysis?; How can insights from biological learners contribute and derive new theoretic perspectives to computational learning systems, neuromorphic engineering, materials science, and nanotechnology? Biological and non-biological systems and social systems can all display learning. What can integration across these different domains contribute to a general understanding of learning? Award amount \$600,000.

Deadline LOI October 6, 2019

NSF 17-573 National Science Foundation – Advanced Informal STEM Learning (AISL) 17-573

LOI Intent deadline October 6, 2019 5pm pacific standard time. research.development@oregonstate.edu

[NSF Advanced Informal STEM Learning \(AISL\)](#)

Next due dates are: November 06, 2019.

NSF Advanced Informal STEM Learning (AISL) is now limited.

Note the changes: The number of proposals for which an organization may be the lead is limited to three (3); and The number of proposals for which one can be PI/Co-PI is limited to three (3); and The minimum one-year budget amount is \$75,000 for an organization in collaborative proposals uploaded as separate submissions from multiple organizations.

Interested - please email research.development@oregonstate.edu

At least 60 days prior to the Project/Program Start Date

Genentech Corporate Giving

<https://www.gene.com/good/giving/corporate-giving/imed>

We're proud to support the work of scientists, researchers, medical professionals and community-based organizations that are finding ways to help those in need and make a lasting, positive impact. Our charitable giving strategy focuses on three core objectives:

1. Advance Scientific Knowledge
2. Enhance Health Outcomes
3. Support Our Local Communities (Washington County)

Genentech provides funding for:

- ❖ Independent Medical Education
- ❖ [Healthcare-Related Charitable Support](#)
- ❖ Philanthropic Charitable Support
- ❖ Scientific Project Support
- ❖ Fellowships

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Rolling Deadline for Funding

E.W. "Al" Thrasher Award

<https://www.thrasherresearch.org/al-thrasher-award?lang=eng>

Ideal applications for the E.W. "Al" Thrasher Award address significant health problems that affect children in large numbers and offer the potential for practical solutions to these problems. Such solutions should be innovative and have the potential for broad applicability with low financial and/or technical barriers to implementation. Hypothesis-driven research is preferred over exploratory, hypothesis-generating research. Projects with a shorter distance to clinical applicability are given priority.

Principal Investigators must be qualified in terms of education and experience to conduct research. A doctoral-level degree is required. This award has a duration of up to three years and the median award amount is \$320,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Rolling Deadline for Funding

Patagonia World Trout Grants Program

The World Trout Initiative funds only groups and efforts working to restore and protect wild, self-sustainable trout, salmon and other fish species within their native range. This includes both indigenous freshwater and saltwater fish. We look for innovative groups that produce measurable results and work on long-term solutions to root causes of the problem. Proposed projects should be quantifiable, with specific goals, objectives and action plans, and should include measures for evaluating success. The funding range is typically between \$5,000 and \$15,000, depending on the specific needs of the project.

***OSU may submit only one proposal to Patagonia per year. If you are interested in applying, please contact Elizabeth Ocampo.**

Rolling LOI No Deadline Announcements for Funding

The G. Harold & Leila Y. Mathers Charitable Foundation Research Grants

<http://www.mathersfoundation.org/index.php/policies/>

The mission of the G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research and applying learnings and discoveries to benefit mankind. Basic scientific research, some with potential translational application, is central to this goal and fundamental to our operating principles.

Rolling LOI No Deadline Announcements for Funding

Simons Foundation - Targeted Grants in Mathematics and Physical Sciences

<https://www.simonsfoundation.org/grant/targeted-grants-in-mps/>

The Targeted Grant in MPS program provides funding for up to five years. The funding level and duration is flexible and should be appropriate based on the type of support requested in the proposal. The program is intended to support high-risk theoretical mathematics, physics and computer science projects of exceptional promise and scientific importance on a case-by-case basis.

No Deadline Announcements for Funding

FFAR – Rapid Outcomes from Agricultural Research (ROAR)

(\$150,000/year)

Timeline: Ongoing Opportunity.

The Rapid Outcomes from Agricultural Research (ROAR) program, created by FFAR, provides nimble deployment of funds to support research and outreach in response to emerging or unanticipated threats to the nation's food supply or agricultural systems. ROAR participants, including but not limited to university researchers, farmers or producers, commodity groups and government officials, may apply for funds prior to an outbreak for development of diagnostics, monitoring and mitigation strategies, or enter into an agreement with FFAR that enables the quick release of funds should an outbreak occur. This funding opportunity will be open biannually for those groups wishing to apply to prepare for a pest or pathogen outbreak that is not already ongoing. Up to \$150,000 per one-year grant is available from FFAR, with the requirement that recipients provide equal or greater matching funds from non-U.S. federal sources.

Cycle 1 Posted Date: February 17, 2018. Responding to a Pest or Pathogen Outbreak

In the event of a pest or pathogen outbreak, submit a one-page concept note to FFAR outlining (1) the consortium members, including researchers, industry representatives and government officials, (2) the source and amount (up to \$150,000) of matching funds for the project and (3) a brief description of the pest or pathogen threat and why it should be considered for rapid funding. FFAR will use the concept note to decide whether or not to invite submission of a full application. This process is designed so that, if a qualifying emergency event occurs, the consortia may rapidly double their response budget (up to \$150,000).

Best approach for: Consortia who are in need of swift deployment of funding in response to a pest or pathogen outbreak.

Eligibility: *The following types of organizations are invited to apply:*

- Public and private institutions of higher education
- Nonprofit organizations
- For-profit organizations

Submit your concept note to Tim Kurt at tkurt@foundationfar.org. Meritorious concepts will be asked to submit a full proposal.

No Deadline Announcements for Funding

The G. Harold & Leila Y. Mathers Charitable Foundation

<http://www.mathersfoundation.org/index.php/policies/>

Life Sciences Research

The mission of the G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research and applying learnings and discoveries to benefit mankind. Basic scientific research, some with potential translational application, is central to this goal and fundamental to our operating principles. Invited proposals from young investigators whose research fits within the Foundation's overall mission will be considered.

Applications are initially reviewed by the Foundation's Executive Director, and subsequently, by the Foundation's Executive Committee. Applications may also be examined by outside reviewers. A response, in the form of approval, rejection, or request for additional information, may be expected within 90-120 days of the submission of the requested information.

No Deadline Announcements for Funding

National Science Foundation – 15-516 Earth Sciences: Instrumentation and Facilities (EAR/IF)

<http://www.nsf.gov/pubs/2015/nsf15516/nsf15516.htm>

15-516 (replaces 11-544).

Proposals Accepted Anytime.

The Instrumentation and Facilities Program in the Division of Earth Sciences (EAR/IF) supports meritorious requests for infrastructure that promotes research and education in areas supported by the Division ([see http://www.nsf.gov/div/index.jsp?div=EAR](http://www.nsf.gov/div/index.jsp?div=EAR)). EAR/IF will consider proposals for: (1) Acquisition or Upgrade of Research Equipment that will advance laboratory and field investigations and student research training opportunities in the Earth sciences. The **maximum request is \$750,000**. The **maximum request for upgrade of research group computing facilities is \$75,000**. (2) Development of New Instrumentation, Techniques or Software that will extend current research and research training capabilities in the Earth sciences. The maximum request is \$750,000. (3) Support of National or Regional Multi-User Facilities that will make complex and expensive instruments, systems of instruments or services broadly available to the Earth science research and student communities. (4) Support for Early Career Investigators to facilitate expedient development and operation of new research infrastructure proposed by the next generation of leaders in the Earth Sciences. The Early Career opportunity specifically allows for submission of a proposal for Acquisition or Upgrade of Research Equipment or Development of New Instrumentation, Techniques or Software which may include additional budget line items associated with support of a new full-time technician who will be dedicated to manage, operate and maintain the instrument(s) being requested. Any request for technical support under this opportunity is limited to three years' duration. The maximum total request is \$1,000,000.

No Deadline Announcements for Funding

Small Business Technology Transfer Program (STTR)

<http://www.sba.gov/offices/headquarters/oca/resources/6828>

STTR is an important small business program that expands funding opportunities in the federal innovation research and development arena. Central to the program is expansion of the public/private sector partnership to include the joint venture opportunities for small business and the nation's premier nonprofit research institutions. STTR's most important role is to foster the innovation necessary to meet the nation's scientific and technological challenges in the 21st century.

Competitive Opportunity for Small Business: STTR is a highly competitive program that reserves a specific percentage of federal R&D funding for award to small business and nonprofit research institution partners. Small business has long been where innovation and innovators thrive. But the risk and expense of conducting serious R&D efforts can be beyond the means of many small businesses.

Conversely, nonprofit research laboratories are instrumental in developing high-tech innovations. But frequently, innovation is confined to the theoretical, not the practical. STTR combines the strengths of both entities by introducing entrepreneurial skills to high-tech research efforts. The technologies and products are transferred from the laboratory to the marketplace. The small business profits from the commercialization, which, in turn, stimulates the U.S. economy.

STTR Qualifications: Small businesses must meet certain eligibility criteria to participate in the STTR Program.
American-owned and independently operated.

For-profit.

Principal researcher need not be employed by small business.

Company size limited to 500 employees.

(No size limit for nonprofit research institution).

The nonprofit research institution must also meet certain eligibility criteria.

Located in the US.

Meet one of three definitions.

Nonprofit college or university.

Domestic nonprofit research organization.

Federally funded R&D center (FFRDC).

The STTR System:

Each year, five federal departments and agencies are required by STTR to reserve a portion of their R&D funds for award to small business/nonprofit research institution partnerships.

Department of Defense.

Department of Energy.

Department of Health and Human Services.

National Aeronautics and Space Administration.

National Science Foundation.

These agencies designate R&D topics and accept proposals.

Three-Phase Program:

Following submission of proposals, agencies make STTR awards based on small business/nonprofit research institution qualification, degree of innovation, and future market potential. Small businesses that receive awards then begin a three-phase program.

Phase I is the startup phase. Awards of up to \$100,000 for approximately one year fund the exploration of the scientific, technical, and commercial feasibility of an idea or technology.

Phase II awards of up to \$750,000, for as long as two years, expand Phase I results. During this period, the R&D work is performed and the developer begins to consider commercial potential. Only Phase I award winners are considered for Phase II.

Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. No STTR funds support this phase. The small business must find funding in the private sector or other non-STTR federal agency funding.

SBA Role: The US Small Business Administration plays an important role as the coordinating agency for the STTR program. It helps the five agencies implement STTR, reviews their progress, and reports annually to Congress on its operation.

SBA is also the information link to STTR. SBA collects solicitation information from all the participating agencies and publishes it electronically in a Pre-Solicitation Announcement (PSA). The PSA is a single source for the topics and anticipated release and closing dates for each agency's solicitation(s).

For more information on the STTR Program, please contact:

**US Small Business Administration, Office of Technology, 409 Third Street, SW, Washington, DC 20416
(202) 205-6450**

All of SBA's programs and services are extended to the public on a nondiscriminatory basis.

No Deadline Announcements for Funding

Michelson Grants

To apply: <http://www.michelsonprizeandgrants.org/michelson-grants/apply> There is **no deadline** for submitting a letter of intent; they are accepted and reviewed on an ongoing basis. If the letter of intent is approved, the applicant will receive a deadline for a full proposal. Proposals must be submitted within two cycles of approval of the LOI.

[Apply for a Grant](#)

[Research Findings](#)

Quick Links

[Resources](#)

[FAQs](#)

Scientific Advisory Board
About the Prize

Found Animals offers **Michelson Grants of up to \$250,000 USD** per year for **up to three years of funding** for research in pursuit of a single-dose, permanent, nonsurgical sterilization product or technology for use in male and female dogs and cats.

As a mission-driven and product-focused program, the Michelson Prize & Grants funds research based on merit rather than a fixed approval rate. To date, we have approved over 30% of proposals submitted and have committed nearly \$14 million to 30+ approved projects across the globe.

No Deadline Announcements for Funding

The Collins Foundation

<http://www.collinsfoundation.org/submission-guidelines>

Eligibility Requirements: The Collins Foundation is committed to equal opportunity for all persons regardless of race, color, national origin, religion, sex, sexual orientation and gender identity, age, disability, or any other legally protected status. It is our intent to consider grant requests only from organizations and agencies that pursue these same principles in their governance, employment practices, and services. The Foundation recognizes that the issue of discrimination is more complex and nuanced than a single policy can convey. Requests may be considered from organizations that have convictions or beliefs of conscience that may not be entirely consistent with the Foundation's values around inclusion. However, organizations that require board members, employees, volunteers, or those receiving services to adhere to specific religious beliefs or lifestyles will automatically be subject to additional scrutiny for eligibility based on the assumption that such requirements are likely to be discriminatory and not compatible with the Foundation's policies or practices. Grant requests are considered only from organizations/agencies that have established their tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and are not "private foundations" as defined under section 509(a) of the Code, or that have tax exemption as a governmental or other publicly-funded entity. Grant requests are considered only from nonprofit organizations/agencies that have current registration with the offices of the Oregon State Attorney General and the Secretary of State.

Grants are made only for projects that directly benefit the residents of Oregon. Grants are not made to specific individuals.

Policy Guidelines: The Foundation will consider only one grant request from the same organization in a twelve month period, unless an additional request is invited by the Foundation.

The Foundation normally will not consider an additional grant request from an organization receiving a multi-year grant until twelve months following the final payment of the multi-year grant.

Grants normally are not made to elementary, secondary, or public higher education institutions; or to individual religious congregations. Grants normally are not made for development office personnel, annual fund-raising activities, endowments, operational deficits, financial emergencies, or debt retirement.

In considering applications for substantial projects, the Foundation prefers to participate with other donors, and encourages the applicant to seek support from other sources to share in the total project.

No Deadline Announcements for Funding

15-527 replaces 13-520 - NSF Research Coordination Networks (RCN)

General (non-targeted) RCN proposals accepted anytime.

<http://www.nsf.gov/pubs/2015/nsf15527/nsf15527.htm>

The goal of the RCN program is to advance a field or create new directions in research or education by supporting groups of investigators to communicate and coordinate their research, training and educational activities across disciplinary, organizational, geographic and international boundaries. RCN provides opportunities to foster new collaborations, including international partnerships, and address interdisciplinary topics. Innovative ideas for implementing novel networking strategies, collaborative technologies, and development of community standards for data and meta-data are especially encouraged. RCN awards are not meant to support existing networks; nor are they meant to support the activities of established collaborations. RCN awards do not support primary research. RCN supports the means by which investigators can share information and ideas, coordinate ongoing or planned research activities, foster synthesis and new collaborations, develop community standards, and in other ways advance science and education through communication and sharing of ideas. Award ceiling not specified.

No Deadline Announcements for Funding

The Cedar Tree Foundation Grants

Letters of Inquiry are accepted anytime.

Does not accept unsolicited proposals.

<http://www.cedartreefound.org/>

The Cedar Tree Foundation is a small family fund created by the late pediatrician and entrepreneur, Dr. David H. Smith. Dr. Smith believed in the power of individuals and organizations to make significant changes in our world, and we reflect that belief in our grant-making. The Cedar Tree Foundation's grant making focuses on the following areas of concern: (1) Sustainable Agriculture, (2) Environmental Education, & (3) Environmental Health. We give particular consideration to proposals that demonstrate strong elements of environmental justice, and conservation. We do not accept unsolicited proposals, but we welcome letters of inquiry for U.S. based work from non-profit organizations working within our program areas. Award ceiling: <\$10,000.

No Deadline Announcements for Funding

USFWS - 2017 National Fish Habitat Action Plan

<http://www.grants.gov/web/grants/view-opportunity.html?oppld=289987>

The National Fish Habitat Action Plan is a national investment strategy to leverage federal and privately raised funds to protect, restore, and enhance the nation's fish and aquatic habitats through partnerships that foster fish habitat conservation. Funds appropriated to the U.S. Fish and Wildlife Service's (Service) Fish and Aquatic Conservation (FAC) Program specifically to implement the Action Plan will be utilized in collaboration with the National Fish Habitat Board and Fish Habitat Partnerships. Fish Habitat Partnerships are the primary work units of the Action Plan, formed around distinct geographic areas, "keystone" fish species, or system types (e.g. large lakes, impoundments, estuaries). Funds will support national and regional science and coordination activities to protect, restore, or enhance fish habitats. All or a portion of project funds may be transferred to partner organizations if the Service lacks the capability to implement a project. Projects must protect, restore, or enhance fish and aquatic habitats or otherwise directly support habitat-related priorities of Fish Habitat Partnerships or the National Fish Habitat Board. Award amounts: \$5,000 - \$300,000. Applications are accepted on a rolling basis.

GRADUATE & UNDERGRADUATE STUDENT RESEARCH FUNDING

Deadline February 1, 2019

PhRMA Foundation Health Outcomes: Pre Doctoral Fellowship

<http://www.phrmafoundation.org/2018-awards/pre-doctoral-fellowship-awards/health-outcomes/>

To provide support to promising students during advanced stages of training and thesis research and for the career development of scientists prepared to engage in health outcomes research. Funds \$25,000 a year for up to two years.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Oregon State University Graduate School Funding Opportunities

<https://gradschool.oregonstate.edu/finance/graduate-fellowships-and-scholarships>

College or Program-Based Fellowships and Scholarships

Over 170 departmental and academic college-based fellowship and scholarship programs sponsored by industry, foundations, and government agencies are available to graduate students at Oregon State University.

[Search for an OSU fellowship](#) that fits your academic goals.

National Science Foundation Award

The [National Science Foundation Graduate Research Fellowship Program \(NSF-GFRP\)](#) is a national award program of prestigious fellowships given each year to a select group of master's and doctoral students in science and engineering fields in recognition of their academic and professional excellence.

PNNL-OSU Distinguished Graduate Research Program

Through the [PNNL-OSU Distinguished Graduate Research Program \(DGRP\)](#), Ph.D. candidates will earn a stipend along with benefits while working under a prestigious graduate committee on nationally relevant research. It is a unique opportunity to tap into the knowledge and world-class research infrastructure available at both institutions.

External Fellowships and Scholarships

Find a [large collection of national fellowships and scholarships](#) where students may apply directly to the granting organization or agency. Also included is a worksheet to organize information about prospective funders and links to web resources and scholarship search engines.

POSTDOCTORAL RESEARCH FUNDING

Deadline January 14, 2019

Gordon and Betty Moore Foundation Moore Inventor Fellows

Letter of Intent January 14, 2019

Deadline March 4, 2019

<https://research.oregonstate.edu/office-research-development/program/gordon-and-betty-moore-foundation-moore-inventor-fellows>

[ce-research-development/program/gordon-and-betty-moore-foundation-moore-inventor-fellows](https://research.oregonstate.edu/office-research-development/program/gordon-and-betty-moore-foundation-moore-inventor-fellows)

The Gordon and Betty Moore Foundation has invited OSU to nominate two candidates for the Moore Inventor Fellowship. Each college may submit a maximum of two candidates for consideration. OSU will make a contribution of \$50,000 in annual support of the inventor's work - The candidate's college must be willing to commit funding of \$50,000 per year for three years to support the candidate's invention research if s/he should be awarded the Moore Invention Fellowship. Nominees must be within 10 years of receiving their terminal degree and must dedicate a minimum of 25% time to the invention during the three-year fellowship. Fellows may use the grant funds to support their own salary to create this opportunity. They may also hire undergraduates, graduate assistants or postdoctoral scholars and purchase services, equipment, or supplies. The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 1, 2019

PhRMA Foundation Research Starter Grants: Translational Medicine and Therapeutics

<http://www.phrmafoundation.org/2018-awards/post-doctoral-fellowships/translational-medicine/>

Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly addresses specific clinician-defined problems and integrates innovative technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies. The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. \$100,000.

Eligibility: Eligible candidates will have doctoral degrees, e.g., PhD, D.Sc, D.Eng, MD, and seek to further develop and refine their skills and understanding of TMT through postdoctoral training. The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 1, 2019

L'Oréal USA Women in Science Fellowship

<http://www.lorealusa.com/csr-commitments/1%E2%80%99or%C3%A9al-usa-for-women-in-science-program>

The L'Oréal USA For Women in Science fellowship program awards five women postdoctoral scientists annually with grants of \$60,000 each for their contributions in Science, Technology, Engineering and Math (STEM) fields and commitment to serving as role models for younger generations. L'Oréal USA partners with the American Association for the Advancement of Science (AAAS) to manage the program's application and peer-review process. Each year, the program attracts talented applicants from diverse STEM fields, representing some of the nation's leading academic institutions and laboratories. Indirect costs are not permitted. \$60,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 1, 2019

Jane Coffin Childs Memorial Fund for Medical Research Cancer Research Fellowships

<https://www.iccfund.org/fellowship-information/>

The Jane Coffin Childs Memorial Fund for Medical Research (known colloquially as the JCC Fund) was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The Fund

has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of three-year postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers. Between twenty-five and thirty three-year Fellowships are awarded annually. \$157,500.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 1, 2019

PhRMA Foundation Post Doctoral Fellowship: Translational Medicine and Therapeutics

<http://www.phrmafoundation.org/2018-awards/post-doctoral-fellowships/translational-medicine/>

Translational medicine and therapeutics is a discipline focused on bridging experimental and computational research and discoveries to their application in clinical practice. To be successful, this requires working with clinicians to identify critical unmet clinical needs. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address such unmet medical needs. Clinical observation becomes the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients.

This award supports individuals engaged in multidisciplinary/collaborative research training programs that will extend their credentials in Translational Medicine and Therapeutics. \$120,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 15, 2019

Dannon Gut Microbiome, Yogurt and Probiotics Fellowship

<http://www.dannon.com/fellowship-application/>

The Dannon Company is accepting applications to its Dannon Gut Microbiome, Yogurt and Probiotics Dannon Fellowship Grant program. Established in 2012, the program has expanded to include the gut microbiome in recognition of its remarkable potential on the human body — including immune system health, brain health, and proper digestion and absorption. To date, the grant has supported research on the use of foods as a delivery vector for beneficial bacteria, technology for studying the adaptation of fermentative microbes to milk, the effects of protein fermentation on the human microbiota and digestive health, and the relationship between probiotics, the gut microbiome, and brain function. Through the program, grants of \$25,000 will be awarded to two graduate students who show strong interest in exploring the gut microbiome, probiotics, and/or yogurt. To be eligible, applicants must be a citizen of the United States; a current, full-time graduate student; and prepared to do his/her research at an accredited U.S. institution during the 2019-20 academic year.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 15, 2019

American Mathematical Society AMS Congressional Fellowship

<https://www.ams.org/programs/ams-fellowships/ams-aaas/ams-aaas-congressional-fellowship>

The American Mathematical Society (AMS), in conjunction with the American Association for the Advancement of Science (AAAS), sponsors the fellowship. It includes an orientation on congressional and executive branch operations, and a year-long seminar series on issues involving science, technology and public policy.

The AMS Congressional Fellowship is part of the AAAS Science & Technology Fellowship program, which provides a unique public policy learning experience, demonstrates the value of science-government interaction, and brings a technical background and external perspective to the Congressional decision-making process.

Prospective Fellows must demonstrate expertise in an area of mathematical sciences; possess a good scientific and technical background; understand and demonstrate sensitivity toward political and social issues; and, most importantly, display a strong interest and some experience in applying personal knowledge toward solving societal problems. \$81,548.

Applicants must be U.S. citizens, holding a Ph.D. in mathematics by the application deadline. Federal employees are not eligible. An AMS Fellowship Committee makes the selection.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 15, 2019

Medical Research Foundation (MRF) Early Clinical Investigator Grant

<https://www.ohsu.edu/xd/about/foundation/about/medical-research-foundation/grants.cfm>

Through this award, the MRF supports promising biomedical exploration and the development of research careers in clinical investigation in Oregon. Principal investigators must be a post-doctoral trainee or clinical fellow with specific plans for a career in clinical research. A letter of support from the department chair or division head and from the director of the training program must accompany each application. The Applicant Qualifications Form should be completed by the applicant's mentor and included with the application and support letters. \$20,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 17, 2019

American Association for Cancer Research AACR-AstraZeneca Ovarian Cancer Research Fellowship

<https://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=58>

The AACR-AstraZeneca Ovarian Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct ovarian cancer research and to establish a successful career path in this field. The research proposed for funding must have direct applicability to ovarian cancer with a specific focus on DNA damage repair pathways and may be basic, translational, clinical, or epidemiological in nature. Any proposals that address topics unrelated to DNA damage repair pathways in ovarian cancer will NOT be accepted. \$120,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline February 26, 2019

RFA-CA-19-029 NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed)

Application Due Date(s) February 26, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this Funding Opportunity Announcement.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Not Applicable.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-029.html>

Companion Funding Opportunity [RFA-CA-19-030](#) [K99/R00](#) Career Transition Award/Research Transition Award

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.

Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA ([RFA-CA-19-030](#)).

Deadline March 1, 2019

The National Academies of Sciences, Engineering, and Medicine

The National Academies of Sciences, Engineering, and Medicine sponsors awards for postdoctoral and senior researchers at [participating federal laboratories and affiliated institutions](#). These awards include generous stipends ranging from \$45,000 - \$80,000 per year for recent Ph.D. recipients, and higher for additional experience. Limited graduate level awards are also available. These awards provide the opportunity for recipients to do independent research in some of the best-equipped and staffed laboratories in the U.S. Research opportunities are open to U.S. citizens, permanent residents, and for some of the laboratories, foreign nationals.

Four annual review cycles:

- February: Opens December 1; Closes February 1
- May: Opens March 1; Closes May 1
- August: Opens June 1; Closes August 1
- November: Opens September 1; Closes November 1

Applicants should contact prospective Research Adviser(s) at the lab(s) prior to the application deadline to discuss their research interests and funding opportunities.

Thank you for your assistance.

For more information: Phone: 202-334-2760, Email: rap@nas.edu, Web: www.nas.edu/rap
Sincerely yours, *H. Ray Gamble* Director, Fellowships Office, 500 Street NW, Washington, DC 20001

Deadline At least 60 days prior to the project/program start date

Genentech – Fellowships

<https://www.gene.com/good/giving/corporate-giving/fellowships>

Fellowships are for grants to independent professional organizations, independent charitable organizations, or other eligible institutions, where the funds are used to support advanced study by clinical and research professionals at an accredited university or teaching institution.

No Deadline Announcements for Funding

Cedar Tree Foundation Grants/David H. Smith Conservation Research Fellowship

<http://www.cedartreefound.org/smith.html>

The David H. Smith Conservation Research Fellowship, the nation's premier postdoctoral program in conservation biology, seeks to find solutions to the most pressing conservation challenges in the United States. The Smith Fellows program was established in 1998 by the late Dr. David H. Smith, founder of the Cedar Tree Foundation. Each Fellow's research is conducted in partnership with a major academic institution and an "on the ground" conservation organization, to help bridge the gap between theory and application. The Fellowship program is a collaboration of the Society for Conservation Biology and the Cedar Tree Foundation.

The Cedar Tree Foundation reviews LOIs four times a year (November, January, March, and June). You should hear from us within a month after your LOI was reviewed. If that time passes and you have not heard from us, please email or call. Additional Information about the Smith Fellows Program: [Smith Fellows Website](#).

Letters of inquiry should be no longer than three pages in length. In addition, please include an organizational budget, as well as a project budget if you are seeking project support. If you are applying for a grant of \$10,000 or less, please send an LOI that describes the problem you are addressing, your project plan, and your goals for the grant period. For all other grants, your 3 page LOI should address these questions:

1) What problems are you solving? 2) How are you addressing these problems? What proof do you have that this is an effective solution? 3) What does success look like? 4) How much money do you need? And how does this amount fit into your revenue strategy? 5) How will you measure and report progress? In lieu of answering these questions, you may attach your business plan.